Managing Side Effects From EGFR Inhibitors (April 10, 2018)

CancerConnect News: Epidermal Growth Factor Receptor (EGFR) inhibitor drugs are a type of precision cancer medicine commonly used to treat lung, colon, head and neck and other cancers that over express the EGFR.  There are several EGFR inhibitor drugs... Continue Reading

Spring into Action For Oral, Head, and Neck Cancer Awareness Week! (April 3, 2018)

CancerConnect News: As the month of April brings head and neck cancer into focus, it’s time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer... Continue Reading

Guidelines for Human Papilloma Virus Testing in Head and Neck Carcinomas (February 6, 2018)

CancerConnect News:  The Centers for Disease Control and Prevention estimates that in the United States, there are more than 16,000 individuals diagnosed with Human Papilloma Virus (HPV)-positive OroPharyngeal Squamous Cell Carcinoma (OPSCC) each year... Continue Reading

Depressive Symptoms Linked to Shorter Survival in Patients with Head and Neck Cancer (January 31, 2018)

CancerConnect News:  In a study of patients with head and neck cancer, even mild depressive symptoms were associated with poorer overall survival according to a team of doctors from the University of Louisville who published their findings in Cancer... Continue Reading

Head and Neck Cancer Patients at Risk of Cognitive Problems Following Treatment (January 8, 2018)

CancerConnect News: Patients who survive head and neck cancer may be more likely to experience declines in mental function according to the results of a recent study. The findings are drawn from cognitive assessments for 80 survivors of head and neck... Continue Reading

U.S. FDA Removes Clinical Hold on CEL-SCI’s Phase 3 Head & Neck Cancer Trial (August 21, 2017)

CEL-SCI Corporation today announced it has received a letter from the U.S. Food and Drug Administration (FDA) stating that the clinical hold that had been imposed on the Company’s Phase 3 cancer study with Multikine* (Leukocyte Interleukin, Inj.) has... Continue Reading

Head and Neck Cancer-What You Need to Know (August 14, 2017)

Head and neck cancer includes a number of different malignant cancers that develop in or around the throat, larynx (voice box), nose, sinuses and mouth. Globally, head and neck cancer is the seventh most common type of cancer with an estimated 400,000-600,000... Continue Reading

Targeted radiotherapy for head and neck cancer could reduce the risk of dry mouth (February 22, 2017)

A troublesome side effect of radiation therapy treatment of cancers involving the head and neck is dry mouth.  This occurs as a consequence of radiation damage to the salivary glands.  According to a new study, changing the intensity of radiotherapy... Continue Reading

Nearly half of U.S. men actively infected with HPV, study finds HPV-linked cancers on the rise in men, but nearly 9 in 10 vaccine-eligible men are unvaccinated! (February 20, 2017)

By Rachel Tompa / Fred Hutch News Service The most common sexually transmitted infection in the U.S. has a bit of a twist. It’s what’s known as a “subclinical infection” — those infected suffer no immediate consequences, but years later have... Continue Reading

Twice-daily radiation therapy reduces mortality from head and neck cancer (February 14, 2017)

Treating head and neck cancer patients with a twice-daily radiation therapy schedule combined with chemotherapy could save more lives, according to new research presented at the European Cancer Congress 2017.1 Around 600,000 people are diagnosed with... Continue Reading

Latest Head and Neck Cancer News By Stage


General Head and Neck Cancer

Twice-daily radiation therapy reduces mortality from head and neck cancer (February 14, 2017)

Treating head and neck cancer patients with a twice-daily radiation therapy schedule combined with chemotherapy could save more lives, according to new research presented at the European Cancer Congress 2017.1 Around 600,000 people are diagnosed with... Continue Reading

Opdivo Approved for Advanced Head and Neck Cancer (November 28, 2016)

The United States Food and Drug Administration (FDA) has approved the immunotherapeutic agent, Opdivo® (nivolumab) for the treatment of advanced head and neck cancer. Specifically,  the indication is for the treatment of squamous cell carcinoma of the... Continue Reading

PET/CT Combined More Effective Than MRI in Monitoring Head and Neck Cancer Patients’ Response to Treatment (October 5, 2016)

According to a recent study, combining PET/CT to monitor response to treatment in head and neck cancer patients appears more effective than MRI. Using PET/CT may better inform doctors whether treatment for head and neck cancer is working after just one... Continue Reading

Keytruda® Approved for Advanced Head and Neck Cancer (September 7, 2016)

The United States Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) for the treatment of advanced head and neck cancer that has stopped responding to platinum-based chemotherapy agents.1 Globally, head and neck cancer comprises... Continue Reading

Compliance with Radiation Schedules Improves Survival in Head and Neck Cancer (June 9, 2016)

Patients with head and neck cancer who comply with their scheduled radiation treatments have significantly improved outcomes compared to those who miss 2 or more of their appointments within the prescribed time period. These results were recently published... Continue Reading

More General Head and Neck Cancer